InVivo Therapeutics Holdings Corp., a Cambridge company developing technologies for the treatment of spinal cord injuries and neurotrauma, said that Francis M. Reynolds has resigned from his positions as chairman, chief executive, and chief financial officer of the company due to his medical condition and that Michael J. Astrue is now as interim CEO
Astrue is currently the non-executive chairman of Vivus, Inc., a Nasdaq-listed biopharmaceutical company, InVivo Therapeutics said in a press release. He served as the interim CEO of Epix Pharmaceuticals Inc. from 2005 to 2006 and previously served as the president and CEO of Transkaryotic Therapies Inc. from 2003 to 2005.
Sean Moran, the company’s director of finance will now serve as chief financial officer.
The company was founded based on proprietary technology co-invented by Robert S. Langer, a professor at the Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital.
In a statement, Langer said, “The science, engineering and clinical work at InVivo have been outstanding and will continue to be outstanding with the team we have in place at InVivo.”